Hyundai Pharm - Asset Resilience Ratio

Latest as of May 2026: 5.02%

Hyundai Pharm (004310) has an Asset Resilience Ratio of 5.02% as of May 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hyundai Pharm (004310) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩11.29 Billion
≈ $7.65 Million USD Cash + Short-term Investments

Total Assets

₩224.69 Billion
≈ $152.27 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Hyundai Pharm's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 004310 total assets.

Liquid Assets Composition Over Time

This chart breaks down Hyundai Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 004310 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩11.29 Billion 5.02%
Total Liquid Assets ₩11.29 Billion 5.02%

Asset Resilience Insights

  • Limited Liquidity: Hyundai Pharm maintains only 5.02% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Hyundai Pharm Industry Peers by Asset Resilience Ratio

Compare Hyundai Pharm's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Yunnan Baiyao Group Co Ltd
SHE:000538
Drug Manufacturers - Specialty & Generic 8.38%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 2.51%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 9.04%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%

Annual Asset Resilience Ratio for Hyundai Pharm (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Hyundai Pharm.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-11-30 0.16% ₩267.91 Million
≈ $181.56K
₩163.22 Billion
≈ $110.61 Million
-0.01pp
2024-11-30 0.17% ₩271.73 Million
≈ $184.15K
₩156.40 Billion
≈ $105.99 Million
-1.40pp
2023-11-30 1.58% ₩2.44 Billion
≈ $1.65 Million
₩154.63 Billion
≈ $104.79 Million
-0.78pp
2022-11-30 2.36% ₩4.27 Billion
≈ $2.89 Million
₩181.16 Billion
≈ $122.77 Million
+2.00pp
2021-11-30 0.35% ₩580.10 Million
≈ $393.13K
₩163.86 Billion
≈ $111.04 Million
-4.20pp
2020-11-30 4.55% ₩7.17 Billion
≈ $4.86 Million
₩157.50 Billion
≈ $106.74 Million
+4.17pp
2013-11-30 0.38% ₩543.24 Million
≈ $368.14K
₩143.40 Billion
≈ $97.18 Million
+0.15pp
2012-11-30 0.23% ₩343.24 Million
≈ $232.61K
₩149.90 Billion
≈ $101.59 Million
+0.01pp
2011-11-30 0.22% ₩343.24 Million
≈ $232.61K
₩156.95 Billion
≈ $106.36 Million
--
pp = percentage points

About Hyundai Pharm

KO:004310 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$185.63 Million
₩273.92 Billion KRW
Market Cap Rank
#16899 Global
#656 in Korea
Share Price
₩8860.00
Change (1 day)
-1.01%
52-Week Range
₩3545.00 - ₩14340.00
All Time High
₩14340.00
About

Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, a… Read more